Chemicals

2,6-Difluorobenzoyl isocyanate

We are 2,6-Difluorobenzoyl isocyanate CAS:60731-73-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2,6-Difluorobenzoyl isocyanate

CAS.NO:60731-73-9

Synonyms:2,6-Difluorobenzoyl isocyanate

2,6-difluoro-benzoylisocyanate

2,5-DIFLUORO-7,7,8,8-TETRACYANOQUINODIMETHANE

Physical and Chemical Properties:

Density 1.32 g/cm3

Boiling Point 66ºC (0.2 mmHg)

Melting Point 140-143.3ºC

Molecular Formula C8H3F2NO2

Molecular Weight 183.11200

Index of Refraction 1.511

Specification:

Appearance:White powder

Assay:≥98.0%

Packing:25 kg/drum, can also be packaged according to customer requirements

Storage:Store in a cool, ventilated place

Application:Intermediate of Hexaflumuron(CAS:86479-06-3)、Diflubenzuron(CAS:35367-38-5)、Chlorfluazuron(CAS:71422-67-8)、Flufenoxuron(CAS:101463-69-8)、Fluazuron(CAS:86811-58-7)、Novaluron(CAS:116714-46-6)、Lufenuron(CAS:103055-07-8) and Teflubenzuron(CAS:83121-18-0).

2,6-Difluorobenzoyl isocyanate

Related News: FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus.9- (2-BroMo-fenil) -9-fenil-9H-fluoreno CAS:1998216-26-4 FT819 is derived from a clonal master engineered induced pluripotent stem cell (iPSC) line with complete elimination of T-cell receptor (TCR) expression and a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus.Ethyl 2-oxo-4-phenylbutyrate CAS:64920-29-2 With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand.(3-metil-4- (2,2,2-trifluoroetoxi) piridin-2-il) metanol CAS:103577-66-8 With the global industrial division of labor and the change in the business model of multinational pharmaceutical companies, the outsourced market for patented drug substances will further expand.With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved.

Product Name
2,2′-Dibromodiethyl ether	View Details
2,5-Dibromo-3-methylpyridine	View Details
3-Bromo-6-hydroxy-2-methylpyridine	View Details